ASH 2022 | New therapeutic approaches targeting XPO1-overexpression in TP53-mutated myeloid malignancies
Eric Padron
• 9 Dec 2022
In this video, Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, discusses overexpression of XPO1 in TP53-mutated myeloid malignancies, which has been found to be a mechanism of resistance to eprenetapopt and azacitidine, opening up the possibility of new therapeutic approaches. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte: Research Funding; Blueprint: Honoraria; Taiho: Honoraria; BMS: Research Funding; Kura: Research Funding; Stemline: Honoraria; Syntrix Pharmaceuticals: Research Funding.
